APP
KURA icon

Avantax Planning Partners’s Kura Oncology KURA Stock Holding History

Avantax Planning Partners’s Portfolio KURA Stock Details KURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-151
Closed -$3K – 788
2018
Q3 		$3K Buy
+151
New +$2.9K ﹤0.01% 1260

Other funds holding KURA

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CTA
Carillon Tower Advisers St. Petersburg, Florida $16.4B AUM 64.75% 1-Year Est. Return

Avantax Planning Partners's KURA Position: Q4 2018 in Review

Avantax Planning Partners sold out of Kura Oncology (KURA) in Q4 2018, closing a stake of 151 shares — an estimated $3K sold.

Avantax Planning Partners first reported a position in KURA in Q3 2018 and held it in 1 quarter. The position peaked at $3K in Q3 2018. 99 funds tracked by Wall St. Rank hold KURA as of Q4 2018.

  • Avantax Planning Partners reported no remaining Kura Oncology position as of Q4 2018 after selling out during the quarter.
  • Avantax Planning Partners sold 151 Kura Oncology shares in Q4 2018, an estimated $3K.
  • Avantax Planning Partners first reported a position in Kura Oncology in Q3 2018 and held it in 1 quarter.
  • Avantax Planning Partners's Kura Oncology position peaked at $3K in Q3 2018.
  • 99 funds tracked by Wall St. Rank held Kura Oncology as of Q4 2018.

Based on Avantax Planning Partners's 13F filing for Q4 2018, filed 14 Feb 2019.